We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

155 hedge funds and large institutions have $508M invested in Eagle Pharmaceuticals, Inc. in 2021 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 64 increasing their positions, 54 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 54

7% less funds holding

Funds holding: 166 → 155 (-11)

11% less capital invested

Capital invested by funds: $574M → $508M (-$65.7M)

41% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 22

Holders
155
Holders Change
-11
Holders Change %
-6.63%
% of All Funds
2.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
64
Reduced
54
Closed
22
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BIP
Brandes Investment Partners
California
+$10.5M
2
SGCIA
Smith Graham & Co Investment Advisors
Texas
+$5.96M
3
KCM
Kennedy Capital Management
Missouri
+$5.26M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$2.28M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.93M

Top Sellers

Rank Fund Capital Flow
1
PWAM
Park West Asset Management
California
-$15.9M
2
AC
Armistice Capital
New York
-$7.99M
3
Citadel Advisors
Citadel Advisors
Florida
-$6.75M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$4.8M
5
Norges Bank
Norges Bank
Norway
-$4.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
KCM
26
Kennedy Capital Management
Missouri
$4.72M +$5.26M +113,180 New
Two Sigma Advisers
27
Two Sigma Advisers
New York
$4.66M +$1.38M +29,700 +36%
Principal Financial Group
28
Principal Financial Group
Iowa
$4.62M +$106K +2,286 +2%
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$4.51M +$2.28M +49,174 +83%
Russell Investments Group
30
Russell Investments Group
United Kingdom
$4.06M +$572K +12,321 +14%
Citadel Advisors
31
Citadel Advisors
Florida
$3.74M -$6.75M -145,422 -62%
Millennium Management
32
Millennium Management
New York
$3.61M +$1.11M +23,909 +38%
Norges Bank
33
Norges Bank
Norway
$3.55M -$4.04M -87,033 -51%
FP
34
Foundry Partners
Minnesota
$3.29M -$135K -2,905 -4%
Charles Schwab
35
Charles Schwab
California
$3.21M +$84K +1,809 +2%
JP Morgan Chase
36
JP Morgan Chase
New York
$2.87M -$316K -6,813 -9%
Bank of America
37
Bank of America
North Carolina
$2.73M -$89K -1,916 -3%
AQR Capital Management
38
AQR Capital Management
Connecticut
$2.56M +$777K +16,724 +37%
William Blair & Company
39
William Blair & Company
Illinois
$2.47M +$438K +9,432 +19%
SG Americas Securities
40
SG Americas Securities
New York
$2.34M -$187K -4,032 -7%
Wells Fargo
41
Wells Fargo
California
$2.22M +$371K +7,997 +18%
N
42
Nuveen
North Carolina
$2.2M +$58.8K +1,267 +2%
Citigroup
43
Citigroup
New York
$1.78M +$1.64M +35,394 +485%
PPA
44
Parametric Portfolio Associates
Washington
$1.66M +$112K +2,402 +6%
SGI
45
Summit Global Investments
Utah
$1.61M +$326K +7,021 +22%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$1.52M +$66K +1,422 +4%
CIA
47
Capital Impact Advisors
Massachusetts
$1.5M – – –
AllianceBernstein
48
AllianceBernstein
Tennessee
$1.47M +$306K +6,590 +23%
GC
49
Globeflex Capital
California
$1.43M – – –
PAMU
50
Pictet Asset Management (UK)
United Kingdom
$1.41M -$246K -5,300 -14%
1
2
3 4 5

EGRX Hedge Fund Activity: Q1 2021 in Review

155 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q1 2021, worth a combined $508M — down 11% from $574M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of EGRX and 13 opened new positions — a net loss of 9 holders — while 54 trimmed existing stakes and 64 added.

The largest buyer was Brandes Investment Partners, adding an estimated $10.5M. The largest seller was Park West Asset Management, cutting an estimated $15.9M.

  • 155 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q1 2021, down from 166 in Q4 2020.
  • Funds reported $508M of Eagle Pharmaceuticals, Inc. stock for Q1 2021, down 11% quarter-over-quarter.
  • 13 funds opened new Eagle Pharmaceuticals, Inc. positions in Q1 2021 and 22 closed out, a net change of -9 holders.
  • The largest Eagle Pharmaceuticals, Inc. buyer in Q1 2021 was Brandes Investment Partners, an estimated $10.5M added.
  • The largest Eagle Pharmaceuticals, Inc. seller in Q1 2021 was Park West Asset Management, an estimated $15.9M sold.

Based on aggregated 13F filings for Q1 2021.